Interferon alfa-2b

Interferon alfa-2b is a recombinant form of the type I interferon protein used as a biopharmaceutical for the treatment of various viral infections and cancers. It is produced through recombinant DNA technology using ''E. coli'' bacteria. This immunotherapy agent functions by modulating the immune system and exerting direct antiproliferative effects on malignant cells.

Medical uses

It is indicated for the treatment of chronic hepatitis B and chronic hepatitis C, often in combination with other agents like ribavirin. In oncology, it is used for conditions such as hairy cell leukemia, follicular lymphoma, malignant melanoma, and AIDS-related Kaposi's sarcoma. It is also employed as an adjuvant therapy following surgical resection in patients with high-risk melanoma. Furthermore, it has applications in treating condylomata acuminata caused by the human papillomavirus.

Adverse effects

Common adverse effects include a flu-like syndrome characterized by fever, chills, myalgia, and headache, which often diminish with continued therapy. Significant hematologic toxicity, such as neutropenia and thrombocytopenia, is frequently observed. Neuropsychiatric effects, including depression, irritability, and insomnia, can be severe and may necessitate discontinuation. Other notable risks include autoimmune disorders like thyroiditis, cardiovascular effects such as hypotension or arrhythmia, and potential for severe hepatotoxicity.

Pharmacology

As a recombinant protein, it binds to specific cell surface receptors, namely the interferon-α/β receptor, activating the JAK-STAT signaling pathway. This leads to the transcription of numerous interferon-stimulated genes, resulting in the inhibition of viral replication within host cells. Its antiproliferative action against tumor cells is mediated through the induction of cell cycle arrest and apoptosis. The drug is metabolized primarily in the kidney and has a relatively short elimination half-life.

History

The development followed the pioneering work on interferons by Alick Isaacs and Jean Lindenmann at the National Institute for Medical Research in London. The recombinant version was cloned and expressed in the late 1970s by scientists at Biogen and Schering-Plough, utilizing technology from Genentech. It received approval from the U.S. Food and Drug Administration in 1986 for the treatment of hairy cell leukemia, marking one of the first successful therapeutic recombinant proteins. Its approval for hepatitis B and hepatitis C significantly altered the management of these chronic liver diseases in the 1990s.

Society and culture

Marketed under the brand name **Intron A** by Schering-Plough (now part of Merck & Co.), it has been a significant product in the biotechnology industry. Its high cost and demanding treatment regimen, involving frequent injections, have been subjects of discussion in health economics. The drug's role was highlighted during the HIV/AIDS epidemic for treating Kaposi's sarcoma. The development of direct-acting antiviral agents for hepatitis C, such as those from Gilead Sciences, has largely superseded its use for that indication in the developed world.

Category:Antivirals Category:Interferons Category:World Health Organization essential medicines